OP0219 Early onset of efficacy with apremilast monotherapy in biologic-naÏve patients with active psoriatic arthritis: a phase 3b, randomized, controlled trial
Peter Nash(Griffith University), Aelion Ja(Middle Tennessee Research Institute), Jessica A. Walsh(VA Salt Lake City Healthcare System), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Kamal Ohson(Memorial University of Newfoundland), JJ Gómez-Reino(Complejo Hospitalario Universitario de Santiago), Lichen Teng(Harbin Medical University), Duc Thanh Nguyen
Cited by 3
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis
|Arthritis Research & Therapy|2015|116
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study
|Arthritis Research & Therapy|2012|114